Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

LDL-Cholesterol-Lowering Therapy

Angela Pirillo  1   2 , Giuseppe D. Norata  3   1 , Alberico L. Catapano  3   2
Arnold von Eckardstein  1 , Christoph J. Binder  2
, editors.
In: Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet]. Cham (CH): Springer; 2022.
.
Affiliations
Free Books & Documents
Review

LDL-Cholesterol-Lowering Therapy

Angela Pirillo et al.
Free Books & Documents

Excerpt

The causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease. In the last decades, statins have been used as the main therapeutic approach to lower plasma cholesterol levels; however, the presence of residual lipid-related cardiovascular risk despite maximal statin therapy raised the need to develop additional lipid-lowering drugs to be used in combination with or in alternative to statins in patients intolerant to the treatment. Several new drugs have been approved which have mechanisms of action different from statins or impact on different lipoprotein classes.

PubMed Disclaimer

References

    1. Ahn CH, Choi SH (2015) New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J 39:87–94. https://doi.org/10.4093/dmj.2015.39.2.87 - DOI - PMC - PubMed
    1. Akdim F, Stroes ES, Sijbrands EJ et al (2010a) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 55:1611–1618. https://doi.org/10.1016/j.jacc.2009.11.069 - DOI - PubMed
    1. Akdim F, Visser ME, Tribble DL et al (2010b) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105:1413–1419. https://doi.org/10.1016/j.amjcard.2010.01.003 - DOI - PubMed
    1. Akdim F, Tribble DL, Flaim JD et al (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 32:2650–2659. https://doi.org/10.1093/eurheartj/ehr148 - DOI - PubMed
    1. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1 - DOI - PubMed

LinkOut - more resources